A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate (Q35316783)

From Wikidata

Jump to navigation Jump to search

scientific article published on December 22, 2010

Language	Label	Description	Also known as
English	A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate	scientific article published on December 22, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

8

object named as

George Wilding

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Michael A. Carducci

5

object named as

Michael Carducci

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

author name string

Justine Yang Bruce

1

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Jens Eickhoff

2

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Roberto Pili

3

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Theodore Logan

4

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Jamie Arnott

6

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Anthony Treston

7

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Glenn Liu

9

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Michael Carducci

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21174224

20 November 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21174224

20 November 2024

publication date

22 December 2010

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

full work available at URL

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191229

0 references

https://europepmc.org/articles/pmc3191229?pdf=render

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21174224

20 November 2024

https://europepmc.org/articles/PMC3191229

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21174224

20 November 2024

https://europepmc.org/articles/PMC3191229?pdf=render

Portable Document Format

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21174224

20 November 2024

https://doi.org/10.1007/s10637-010-9618-9

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21174224

20 November 2024

https://link.springer.com/content/pdf/10.1007/s10637-010-9618-9.pdf

Portable Document Format

1 reference

10.1007/S10637-010-9618-9

https://api.crossref.org/works/10.1007/S10637-010-9618-9

20 November 2024

https://link.springer.com/article/10.1007/s10637-010-9618-9/fulltext.html

1 reference

10.1007/S10637-010-9618-9

https://api.crossref.org/works/10.1007/S10637-010-9618-9

20 November 2024

http://link.springer.com/content/pdf/10.1007/s10637-010-9618-9

1 reference

10.1007/S10637-010-9618-9

https://api.crossref.org/works/10.1007/S10637-010-9618-9

20 November 2024

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

794-802

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191229

12 July 2018

A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191229

12 July 2018

Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191229

12 July 2018

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191229

12 July 2018

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191229

12 July 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191229

12 July 2018

Mechanism of action of 2-methoxyestradiol: new developments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191229

12 July 2018

2-Methoxyestradiol, a promising anticancer agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191229

12 July 2018

2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191229

12 July 2018

Mucoadhesive nanoparticulate systems for peptide drug delivery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191229

12 July 2018

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191229

12 July 2018

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191229

12 July 2018

2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191229

12 July 2018

The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3191229

12 July 2018

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9618-9

21 January 2018

Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9618-9

21 January 2018

Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9618-9

21 January 2018

A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9618-9

21 January 2018

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9618-9

21 January 2018

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9618-9

21 January 2018

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9618-9

21 January 2018

2-Methoxyestradiol Arrests Cells in Mitosis without Depolymerizing Tubulin

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9618-9

21 January 2018

Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators

1 reference

https://pubmed.ncbi.nlm.nih.gov/21174224

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-010-9618-9

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35316783&oldid=2278432750"